Education
About Us
Working with TipRanks
Follow Us
Salarius Pharmaceuticals Inc (SLRX)
NASDAQ:SLRX
RESEARCH TOOLSreports
SLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $7.20
Previous CloseN/A
Volume13.28K
Average Volume (3M)2.46M
Market Cap
$1.31M
Enterprise Value$13.90M
Total Cash (Recent Filing)$1.80M
Total Debt (Recent Filing)$112.23K
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding2,127,286
10 Day Avg. Volume293,806
30 Day Avg. Volume2,461,502
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.36
Enterprise Value/Market Cap10.63
Enterprise Value/Revenue388.37
Enterprise Value/Gross Profit-12.57K
Enterprise Value/Ebitda-0.80
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Salarius Pharmaceuticals News
PremiumCompany Announcements
Salarius Pharmaceuticals Modifies Security Holders’ RightsPremiumCompany Announcements
Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
PremiumCompany Announcements
Salarius Pharmaceuticals Approves Reverse Stock Split
PremiumCompany Announcements
Salarius Pharmaceuticals Granted Nasdaq Compliance ExtensionOptions Prices
Currently, No data available
---
Ownership Overview
2.84%
Insiders
0.45% Mutual Funds
0.72% Other Institutional Investors
98.57% Public Companies and
Individual Investors
SLRX FAQ
What was Salarius Pharmaceuticals Inc’s price range in the past 12 months?
Salarius Pharmaceuticals Inc lowest stock price was $0.45 and its highest was $7.20 in the past 12 months.
What is Salarius Pharmaceuticals Inc’s market cap?
Salarius Pharmaceuticals Inc’s market cap is $1.31M.
When is Salarius Pharmaceuticals Inc’s upcoming earnings report date?
Salarius Pharmaceuticals Inc’s upcoming earnings report date is Aug 06, 2025 which is in 15 days.
How were Salarius Pharmaceuticals Inc’s earnings last quarter?
Salarius Pharmaceuticals Inc released its earnings results on May 08, 2025. The company reported -$1.027 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.027.
Is Salarius Pharmaceuticals Inc overvalued?
According to Wall Street analysts Salarius Pharmaceuticals Inc’s price is currently Overvalued.
Does Salarius Pharmaceuticals Inc pay dividends?
Salarius Pharmaceuticals Inc does not currently pay dividends.
What is Salarius Pharmaceuticals Inc’s EPS estimate?
Salarius Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Salarius Pharmaceuticals Inc have?
Salarius Pharmaceuticals Inc has 2,127,286 shares outstanding.
What happened to Salarius Pharmaceuticals Inc’s price movement after its last earnings report?
Salarius Pharmaceuticals Inc reported an EPS of -$1.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.859%.
Which hedge fund is a major shareholder of Salarius Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SLRX
Company Description
Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. (SLRX) is an oncology-focused pharmaceutical company dedicated to developing innovative therapies for cancer treatment. Operating within the biotechnology and pharmaceuticals sector, the company primarily focuses on epigenetic therapies, striving to address unmet needs in the oncology field. Salarius is actively developing its lead investigational drug, seclidemstat, a differentiated oral LSD1 (lysine-specific demethylase 1) inhibitor, which is being explored for the treatment of various types of cancer, including Ewing sarcoma and other solid tumors.
Technical Analysis
Aptevo Therapeutics
―
ReShape Lifesciences
―
Virpax Pharmaceuticals
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―